Tumor suppressor mechanisms in immune aging

Current Opinion in Immunology

Volumn 21, Issue 4, 2009, Pages 431-439

  Liu, Yan ^a   Sharpless, Norman E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53; RETINOBLASTOMA PROTEIN;

AGING; CANCER GROWTH; CANCER INHIBITION; CELL AGING; CELL CYCLE REGULATION; CHROMOSOME ABERRATION; DNA DAMAGE; DNA REPAIR; GENE ACTIVATION; GENETIC RECOMBINATION; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; TELOMERE; TUMOR SUPPRESSOR GENE;

AGING; ANIMALS; B-LYMPHOCYTES; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA DAMAGE; HOMEOSTASIS; HUMANS; RECOMBINATION, GENETIC; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 68149158208     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2009.05.011     Document Type: Review

References (69)

1. Linton P.J., and Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol 5 (2004) 133-139
2. Ju Z., and Rudolph K.L. Telomeres and telomerase in stem cells during aging and disease. Genome Dyn 1 (2006) 84-103
3. Kudlow B.A., Kennedy B.K., and Monnat Jr. R.J. Werner and Hutchinson-Gilford progeria syndromes: mechanistic basis of human progeroid diseases. Nat Rev Mol Cell Biol 8 (2007) 394-404
4. Ruzankina Y., Asare A., and Brown E.J. Replicative stress, stem cells and aging. Mech Ageing Dev 129 (2008) 460-466
5. Sharpless N.E., and DePinho R.A. Telomeres, stem cells, senescence, and cancer. J Clin Invest 113 (2004) 160-168
6. Kim W.Y., and Sharpless N.E. The regulation of INK4/ARF in cancer and aging. Cell 127 (2006) 265-275
7. Tyner S.D., Venkatachalam S., Choi J., Jones S., Ghebranious N., Igelmann H., Lu X., Soron G., Cooper B., Brayton C., et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 415 (2002) 45-53
8. Maier B., Gluba W., Bernier B., Turner T., Mohammad K., Guise T., Sutherland A., Thorner M., and Scrable H. Modulation of mammalian life span by the short isoform of p53. Genes Dev 18 (2004) 306-319
9. Matheu A., Maraver A., Klatt P., Flores I., Garcia-Cao I., Borras C., Flores J.M., Vina J., Blasco M.A., and Serrano M. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 448 (2007) 375-379. This paper shows that increased expression of Arf and wild-type p53 protects mice from both cancer and aging-related damages, indicating an anti-aging role of Arf/p53 pathway presumably through enhanced DNA damage repair.
10. Dumble M., Moore L., Chambers S.M., Geiger H., Van Zant G., Goodell M.A., and Donehower L.A. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood 109 (2007) 1736-1742. This paper demonstrates that increased activity of p53 causes premature aging of HSCs, while lower dose of p53 abolishes age-associated decline of HSC repopulating capacity. Together with references [7] and [8], this study supports a pro-aging role of p53 pathway.
11. Rane S.G., Dubus P., Mettus R.V., Galbreath E.J., Boden G., Reddy E.P., and Barbacid M. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 22 (1999) 44-52
12. Tsutsui T., Hesabi B., Moons D.S., Pandolfi P.P., Hansel K.S., Koff A., and Kiyokawa H. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol 19 (1999) 7011-7019
13. Matsumura T., Zerrudo Z., and Hayflick L. Senescent human diploid cells in culture: survival, DNA synthesis and morphology. J Gerontol 34 (1979) 328-334
14. Effros R.B., Dagarag M., Spaulding C., and Man J. The role of CD8+ T-cell replicative senescence in human aging. Immunol Rev 205 (2005) 147-157
15. Herbig U., Ferreira M., Condel L., Carey D., and Sedivy J.M. Cellular senescence in aging primates. Science 311 (2006) 1257
16. Aubert G., and Lansdorp P.M. Telomeres and aging. Physiol Rev 88 (2008) 557-579
17. Sharpless N.E., and DePinho R.A. How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol 8 (2007) 703-713
18. Chang S., Multani A.S., Cabrera N.G., Naylor M.L., Laud P., Lombard D., Pathak S., Guarente L., and DePinho R.A. Essential role of limiting telomeres in the pathogenesis of Werner syndrome. Nat Genet 36 (2004) 877-882
19. Allsopp R.C., Morin G.B., DePinho R., Harley C.B., and Weissman I.L. Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. Blood 102 (2003) 517-520
20. Ju Z., Jiang H., Jaworski M., Rathinam C., Gompf A., Klein C., Trumpp A., and Rudolph K.L. Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment. Nat Med 13 (2007) 742-747
21. Rossi D.J., Bryder D., Seita J., Nussenzweig A., Hoeijmakers J., and Weissman I.L. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature 447 (2007) 725-729. This paper examines HSC function with age in mice deficient in several DNA repair pathways and shows that HSC repopulating capacity and self-renewal is defective in the absence of these pathways. This study also provides evidence that endogenous DNA damage accumulates with age in HSCs and supports that DNA damage accumulation plays an important role in HSC aging.
22. Effros R.B. Telomerase induction in T cells: a cure for aging and disease?. Exp Gerontol 42 (2007) 416-420
23. Fauce S.R., Jamieson B.D., Chin A.C., Mitsuyasu R.T., Parish S.T., Ng H.L., Kitchen C.M., Yang O.O., Harley C.B., and Effros R.B. Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes. J Immunol 181 (2008) 7400-7406. This paper represents the first study to use a pharmacological telomerase-based approach to enhance immune function. By showing that a small molecule telomerase activator (TAT2) increases antiviral function of senescent CD8+ CTLs in chronic viral infection, this study provides evidence that telomere shortening plays an important role in immunosenescence caused by chronic infection.
24. Knudson M., Kulkarni S., Ballas Z.K., Bessler M., and Goldman F. Association of immune abnormalities with telomere shortening in autosomal-dominant dyskeratosis congenita. Blood 105 (2005) 682-688
25. Alter B.P., Baerlocher G.M., Savage S.A., Chanock S.J., Weksler B.B., Willner J.P., Peters J.A., Giri N., and Lansdorp P.M. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 110 (2007) 1439-1447
26. Frenck Jr. R.W., Blackburn E.H., and Shannon K.M. The rate of telomere sequence loss in human leukocytes varies with age. Proc Natl Acad Sci U S A 95 (1998) 5607-5610
27. Samani N.J., Boultby R., Butler R., Thompson J.R., and Goodall A.H. Telomere shortening in atherosclerosis. Lancet 358 (2001) 472-473
28. Obana N., Takagi S., Kinouchi Y., Tokita Y., Sekikawa A., Takahashi S., Hiwatashi N., Oikawa S., and Shimosegawa T. Telomere shortening of peripheral blood mononuclear cells in coronary disease patients with metabolic disorders. Intern Med 42 (2003) 150-153
29. Wu X., Amos C.I., Zhu Y., Zhao H., Grossman B.H., Shay J.W., Luo S., Hong W.K., and Spitz M.R. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 95 (2003) 1211-1218
30. Liu Y., Elf S.E., Miyata Y., Sashida G., Liu Y., Huang G., Di Giandomenico S., Lee J.M., Deblasio A., Menendez S., et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 4 (2009) 37-48
31. Chen J., Ellison F.M., Keyvanfar K., Omokaro S.O., Desierto M.J., Eckhaus M.A., and Young N.S. Enrichment of hematopoietic stem cells with SLAM and LSK markers for the detection of hematopoietic stem cell function in normal and Trp53 null mice. Exp Hematol 36 (2008) 1236-1243
32. -/- multipotent progenitors. Nature 453 (2008) 228-232
33. Chin L., Artandi S.E., Shen Q., Tam A., Lee S.L., Gottlieb G.J., Greider C.W., and DePinho R.A. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97 (1999) 527-538
34. Choudhury A.R., Ju Z., Djojosubroto M.W., Schienke A., Lechel A., Schaetzlein S., Jiang H., Stepczynska A., Wang C., Buer J., et al. Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat Genet 39 (2007) 99-105
35. Serrano M., and Blasco M.A. Cancer and ageing: convergent and divergent mechanisms. Nat Rev Mol Cell Biol 8 (2007) 715-722
36. INK4a and Arf may play apposing roles in mammalian aging.
37. Ohkusu-Tsukada K., Tsukada T., and Isobe K. Accelerated development and aging of the immune system in p53-deficient mice. J Immunol 163 (1999) 1966-1972
38. Cheng T., Rodrigues N., Shen H., Yang Y., Dombkowski D., Sykes M., and Scadden D.T. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 287 (2000) 1804-1808
39. van Os R., Kamminga L.M., Ausema A., Bystrykh L.V., Draijer D.P., van Pelt K., Dontje B., and de Haan G. A Limited role for p21Cip1/Waf1 in maintaining normal hematopoietic stem cell functioning. Stem Cells 25 (2007) 836-843
40. CIP is important for maintaining self-renewal of leukemia/hematopoietic stem cells.
41. Migliaccio M., Raj K., Menzel O., and Rufer N. Mechanisms that limit the in vitro proliferative potential of human CD8+ T lymphocytes. J Immunol 174 (2005) 3335-3343
42. Krishnamurthy J., Torrice C., Ramsey M.R., Kovalev G.I., Al-Regaiey K., Su L., and Sharpless N.E. Ink4a/Arf expression is a biomarker of aging. J Clin Invest 114 (2004) 1299-1307
43. Edwards M.G., Anderson R.M., Yuan M., Kendziorski C.M., Weindruch R., and Prolla T.A. Gene expression profiling of aging reveals activation of a p53-mediated transcriptional program. BMC Genomics 8 (2007) 80-92
44. Krishnamurthy J., Ramsey M.R., Ligon K.L., Torrice C., Koh A., Bonner-Weir S., and Sharpless N.E. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 443 (2006) 453-457
45. Janzen V., Forkert R., Fleming H.E., Saito Y., Waring M.T., Dombkowski D.M., Cheng T., DePinho R.A., Sharpless N.E., and Scadden D.T. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 443 (2006) 421-426
46. Molofsky A.V., Slutsky S.G., Joseph N.M., He S., Pardal R., Krishnamurthy J., Sharpless N.E., and Morrison S.J. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature 443 (2006) 448-452
47. INK4a or Arf expression in aged lymphoid progenitors rescues these defects, indicating an important role of INK4a/Arf locus in lymphoid progenitor aging in mice.
48. Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Ibrahim JG, Thomas NE, Sharpless NE: Expression of p16INK4a in peripheral blood T-cells is a biomarker of human aging. Aging Cell 2009, doi:10.1111/j.1474-9726.2009.00489.x. This paper and reference [49] provide evidences that p16INK4a expression in human peripheral blood lymphocytes is associated with chronologic age, genetics, and factors that affect the degree of human aging. These data validate the observations in model system and indicate that p16INK4a expression, determined by chronological age, environmental exposures and genetics, acts as a biomarker of human molecular age.
49. Liu Y., Sanoff H.K., Cho H., Burd C.E., Torrice C., Mohlke K.L., Ibrahim J.G., Thomas N.E., and Sharpless N.E. INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS ONE 4 (2009) e5027
50. Lal A., Kim H.H., Abdelmohsen K., Kuwano Y., Pullmann Jr. R., Srikantan S., Subrahmanyam R., Martindale J.L., Yang X., Ahmed F., et al. p16(INK4a) translation suppressed by miR-24. PLoS ONE 3 (2008) e1864
51. Jacobs J.J., Kieboom K., Marino S., DePinho R.A., and van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397 (1999) 164-168
52. Molofsky A.V., Pardal R., Iwashita T., Park I.K., Clarke M.F., and Morrison S.J. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425 (2003) 962-967
53. Park I.K., Qian D., Kiel M., Becker M.W., Pihalja M., Weissman I.L., Morrison S.J., and Clarke M.F. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423 (2003) 302-305
54. Kotake Y., Cao R., Viatour P., Sage J., Zhang Y., and Xiong Y. pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev 21 (2007) 49-54
55. Bracken A.P., Kleine-Kohlbrecher D., Dietrich N., Pasini D., Gargiulo G., Beekman C., Theilgaard-Monch K., Minucci S., Porse B.T., Marine J.C., et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 21 (2007) 525-530
56. •].
57. Gil J., Bernard D., Martinez D., and Beach D. Polycomb CBX7 has a unifying role in cellular lifespan. Nat Cell Biol 6 (2004) 67-72
58. Lessard J., and Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423 (2003) 255-260
59. van der Lugt N.M., Domen J., Linders K., van Roon M., Robanus-Maandag E., te Riele H., van der Valk M., Deschamps J., Sofroniew M., van Lohuizen M., et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev 8 (1994) 757-769
60. •] provide the evidences that expression of PcG proteins EZH2 or BMI-1 reduces with aging in pancreatic β cells, which is associated with observed increase in p16INK4a expression, diminished β cell mass and phenotypes of T2DM. These results suggest the possibility that a loss of PcG repression with aging contributes to the observed increase in expression of p16INK4a and aging phenotypes noted in several human tissues.
61. Oguro H., Iwama A., Morita Y., Kamijo T., van Lohuizen M., and Nakauchi H. Differential impact of Ink4a and Arf on hematopoietic stem cells and their bone marrow microenvironment in Bmi1-deficient mice. J Exp Med 203 (2006) 2247-2253
62. Bruggeman S.W., Valk-Lingbeek M.E., van der Stoop P.P., Jacobs J.J., Kieboom K., Tanger E., Hulsman D., Leung C., Arsenijevic Y., Marino S., et al. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev 19 (2005) 1438-1443
63. Lagresle C., Gardie B., Eyquem S., Fasseu M., Vieville J.C., Pla M., Sigaux F., and Bories J.C. Transgenic expression of the p16(INK4a) cyclin-dependent kinase inhibitor leads to enhanced apoptosis and differentiation arrest of CD4-CD8-immature thymocytes. J Immunol 168 (2002) 2325-2331
64. Randle D.H., Zindy F., Sherr C.J., and Roussel M.F. Differential effects of p19(Arf) and p16(Ink4a) loss on senescence of murine bone marrow-derived preB cells and macrophages. Proc Natl Acad Sci U S A 98 (2001) 9654-9659
65. Erickson S., Sangfelt O., Heyman M., Castro J., Einhorn S., and Grander D. Involvement of the Ink4 proteins p16 and p15 in T-lymphocyte senescence. Oncogene 17 (1998) 595-602
66. Sharpless N.E., Bardeesy N., Lee K.H., Carrasco D., Castrillon D.H., Aguirre A.J., Wu E.A., Horner J.W., and DePinho R.A. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413 (2001) 86-91
67. Bianchi T., Rufer N., MacDonald H.R., and Migliaccio M. The tumor suppressor p16(Ink4a) regulates T lymphocyte survival. Oncogene 25 (2006) 4110-4115
68. Zindy F., Quelle D.E., Roussel M.F., and Sherr C.J. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15 (1997) 203-211
69. Melk A., Schmidt B.M., Takeuchi O., Sawitzki B., Rayner D.C., and Halloran P.F. Expression of p16INK4a and other cell cycle regulator and senescence associated genes in aging human kidney. Kidney Int 65 (2004) 510-520